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April 7, 2009:1244–7(EMS) is not capable of administering pre-hospital fibrinolysis
and the patient is transported to a nonpercutaneous coronary
intervention (PCI)–capable hospital, the door-to-needle time
should be within 30 min. It is not logical to “start the clock” for
administration of a fibrinolytic in an EMS setting that is not
capable of delivering such a treatment. In contrast, if EMS is
not capable of administering pre-hospital fibrinolysis and the
patient is transported to a PCI-capable hospital, the EMS
arrival-to-balloon time should be within 90 min, emphasizing
the system goal of communication to the PCI-capable hospital
to shorten the delays for arrival of the critical personnel to
perform the procedure.
. The field and transport times in the U.S., in general, are much
longer than those cited by Terkelsen et al. (2), as evidenced by
the findings from ER–TIMI 19 (Early Retavase–Thrombolysis In
Myocardial Infarction 19) trial (4). The Writing Committee (3)
stressed the need for systems efforts to reduce time to reperfu-
sion with the full appreciation, in contrast to the opinion of
Terkelsen et al. (2), that pre-hospital delays are harmful to both
patients treated with fibrinolysis as well as those treated by PCI.
. The explanation regarding the unusual pattern of mortality in
the fibrinolytic-treated patients in the PCAT-2 (Primary Cor-
onary Angioplasty vs. Thrombolysis-2) meta-analysis (5) actu-
ally underscores the concern about using it to buttress the
statement that primary PCI, as compared with fibrinolysis, is
associated with a significant mortality reduction irrespective of
PCI-related delays. The mixing of trial designs and failure to
account for patient characteristics remain substantial shortcom-
ings of the PCAT-2 analysis.
. The statements about the National Registry of Myocardial
Infarction are not correct. The National Registry of Myocardial
Infarction is the largest voluntary myocardial infarction database
in the world and provides data from 2,157 unique hospitals,
more than one-third of all U.S. acute care hospitals. In contrast
to the numbers cited by Terkelsen et al. (2), between 1990 and
2006, there was a switch in the distribution of reperfusion
methods used so that by 2006, 43.2% of patients received
primary PCI and 27.6% received fibrinolysis (6). The real-world
experience from the National Registry of Myocardial Infarction
and the analysis from Pinto et al. (7) remain important
contributions to our global understanding of the complex
decision making in reperfusion for ST-segment elevation myo-
cardial infarction. Age, location of infarction, and time from
onset of occlusion are key determinants of prognosis and it is
logical that they should be factored into decision making about
treatment for ST-segment elevation myocardial infarction.
erkelsen et al. (2) perseverate on technical details of selection of
reperfusion strategy rather than address the need for re-
ngineering of systems of care. Without attention to such systems
fforts it is unlikely we will see further clinically meaningful
hortening of the time from occlusion of a patient’s coronary artery
o restoration of antegrade blood flow in that vessel.
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icrovolt T-Wave Alternans
s There Anything
hat Can Be Done to Save It?
he sobering results reported in the contribution of Chow et al.
1), published in the November 11, 2008, issue of the Journal, calls
or a serious and in-depth reassessment of microvolt T-wave
lternans (MTWA) technology for its role in the identification of
atients with ischemic and nonischemic cardiomyopathy and
ho are most likely to benefit from implantable cardioverter-
efibrillator (ICD) deployment. Previous observational studies
ave concluded that MTWA predicts arrhythmic events and
herapeutic ICD shocks, in patient populations with diverse
ardiac pathologies. In contrast, the prospective study under
onsideration (1)—which comprised 575 patients who met
ADIT-II (Multicenter Automatic Defibrillator Implantation
rial II) criteria for an ICD implantation (post-myocardial infarc-
ion status and an ejection fraction of 30%), had an MTWA
ssessment before the ICD implantation, and were followed for at
east 2 years—showed that the risk of suffering a ventricular
rrhythmic event was no different between the patients with a
egative MTWA test and those with a non-negative MTWA test,
lthough the latter had higher total mortality. What is more
isconcerting is that this study is published simultaneously with
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April 7, 2009:1244–7nother, based on a subgroup of 490 patients from the SCD-
eFT (Sudden Cardiac Death in Heart Failure Trial) cohort (2),
hich also concluded that MTWA testing did not predict arrhyth-
ic events or mortality. After reading these reports, how does one
ct when facing a patient who might be a candidate for an ICD
mplantation? Should one go ahead with the ICD implantation or
esort to testing for MTWA? Does MTWA still have some role to
lay? One approach is to wait and comfort ourselves with the
outine pronouncements that more well-designed studies, enroll-
ng larger number of “representative” patients and with longer
ollow-up periods, are in order. In reference to the latter, a long
ollow-up period has its disadvantages, because one should not
xpect a single, initially carried out MTWA test to be predictive of
linical outcomes of patients afflicted by a changing disease state
ver a protracted period of time, and thus periodic MTWA
ssessment (every 6 to 12 months?) might be advisable. Wouldn’t
his be prudent for other tests (e.g., exercise stress testing), and
hus shouldn’t this also apply to MTWA evaluation? This reader
oes not expect any “light in the tunnel” to be forthcoming by
esorting to “more studies” with “larger study cohorts” and has
ut his hopes only in some “tinkering” with the implemented
TWA testing technology. Vast experience indicates that marked
lterations of the morphology, amplitude, and polarity of the T
aves and J-T intervals are commonplace in both normal subjects
nd patients. Some of these changes can be traced to alterations in
eart rate, but most of them remain unexplained and are encoun-
ered in clinically stable individuals. One wonders as to the impact
f such changes on the magnitude of MTWA. The magnitude of
he MTWA (not reported in the study under consideration [1]) is
f significance for both quantitative and qualitative study designs;
fter all, a cut point of 1.9 V is implemented for the
haracterization of a test as positive/negative/indeterminate. It has
een speculated (not shown) that the MTWA magnitude might be
-wave amplitude-dependent (3), and thus it might be of value to
djust the magnitude of the MTWA by the amplitude of the
orresponding T waves used in the measurement/calculation of
TWA. Such a notion might be more applicable to the time-
omain MTWA methodology using a modified moving average
nalysis, but it applies in principle to the spectral analytic method.
n the latter, one should expect that this “indexing” of MTWA
agnitude values should consider the entire J-T interval in some
orm of representation. However, one should attempt to take the
rst step (however crude) of “indexing” the MTWA magnitude
alues by the corresponding T-wave amplitudes. This should be
pplied separately for patients with normal and prolonged QRS
omplexes. In this context, it might be of value to the readership
or Chow et al. to supply us with the quantitative results of the
TWA of their study and evaluate whether adjusting such
TWA values by the corresponding T-wave amplitudes leads to
n MTWA index with worse, the same, or better prognostic power
han they have identified in their study.
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eply
t is true that despite promising early studies, clinical application of
icrovolt T-wave alternans (MTWA) has become less clear, with
oth the MASTER (Microvolt T Wave Alternans Testing for
isk Stratification of Post-Myocardial Infarction Patients) trial (1)
nd the SCD-HeFT (Sudden Cardiac Death in Heart Failure
rial) substudy (2) failing to demonstrate an association of
TWA with their primary end points. The issue is further
uddied by the conflicting results from the ALPHA (T-wave
lternans in patients with heart failure) study (3), in which
TWA predicted arrhythmic mortality in nonischemic cardiomy-
pathy patients. Although the explanation(s) for such divergent
ndings remain speculative, one possibility is that implantable
ardioverter-defibrillator (ICD) shocks, which were used as end
oints in both the MASTER and SCD-HeFT trials, might be a
oor surrogate for arrhythmic mortality due to lack of specificity.
n a recent MTWA meta-analysis, Hohnloser et al. (4) concluded
hat MTWA studies in which ICD penetration was low and that
sed mortality as the primary end point generally show MTWA to
e a powerful predictor of events. The reverse is true for studies
uch as MASTER and SCD-HeFT, in which ICD penetration
as high and which used ICD shock end points.
Where to go from here with respect to MTWA is a matter of
iffering opinion, but for many, enthusiasm has been replaced by
aution. Attempting to improve prediction through refining inter-
retation of the test (e.g., using MTWA magnitude as a contin-
ous rather than dichotomous index of risk, possibly with adjust-
ent for T-wave amplitude) has conceptual appeal but still
equires clinical validation. In the MASTER trial, exploring
ifferent heart rate cut-off thresholds for defining positive and
egative MTWA test results (i.e., onset heart rate and maximum
egative heart rate) did not improve predictive value (5). Retro-
pective analysis of alternans amplitude as a risk index, as suggested
y Dr. Madias, is certainly possible. In principle, additional
efinements could also be made. For example, because MTWA is
eart rate-dependent, overlap of patient daily heart rate with the
nset heart rate for alternans could be a better index of risk than
hether alternans is present at an arbitrary heart rate threshold of
10 beats/min. Whether trigger-substrate type relationships exist
etween MTWA and, for example, ventricular ectopy are largely
nknown. Utility of MTWA as a component within a “suite” of
oninvasive predictors is also under evaluation in other ongoing
tudies.
With respect to the concept of serial MTWA testing raised by
r. Madias, all MASTER patients were in fact required to
